{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:12:20Z","timestamp":1793686340139,"version":"4.5.1"},"reference-count":166,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007056","name":"Nonin Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007056","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Sj\u00f6gren Syndrome (SS) seems to be associated with a greater \u201coverall risk\u201d of cardiovascular (CV) and cerebrovascular events. Although not conventionally considered a feature of the disease, CV events represent a major burden in SS patients. CV risk is the consequence of a complex combination of multiple factors, including traditional risk factors and disease-related mechanisms. A complex relationships between disease-related features, endothelial dysfunction and traditional risk factor has been suggested. Several drugs are available for treating the systemic manifestations of SS, however they have shown positive effects on different outcomes of the disease, but until today the data on the role of these drugs on CV events are scarse. Given these data, the aim of this review was to evaluate the risk of CV risk in primary SS and the effect of the drugs on this manifestation.<\/jats:p>","DOI":"10.3389\/fimmu.2022.879516","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T01:12:59Z","timestamp":1651799579000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Cardiovascular Involvement in Sj\u00f6gren\u2019s Syndrome"],"prefix":"10.3389","volume":"13","author":[{"given":"Fabiola","family":"Atzeni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Gozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Cafaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Perricone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bartoloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sj\u00f6gren\u2019s Syndrome","volume":"379","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.12203710.1002\/acr.22216","article-title":"Elevated IgG4 Serum Levels Among Primary Sj\u00f6gren\u2019s Syndrome Patients: Do They Unmask Underlying IgG4-Related Disease","volume":"66","author":"Mavragani","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sjogren\u2019s Syndrome Patient Reported Index (ESSPRI): Development of a Consensus Patient Index for Primary Sj\u00f6gren\u2019s Syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheumatol Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sjogren\u2019s Syndrome Disease Activity Index: Development of a Consensus Systemic Disease Activity Index for Primary Sjogren\u2019s Syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann Rheumatol Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.55.7.450","article-title":"Cardiac Manifestations in Primary Sj\u00f6gren\u2019s Syndrome","volume":"55","author":"Gy\u00f6ngy\u00f6si","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2011.26.2.213","article-title":"Complete Atrioventricular Block in Adult Sj\u00f6gren\u2019s Syndrome With Anti-Ro Autoantibody","volume":"26","author":"Sung","year":"2011","journal-title":"Korean J Intern Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.102.9.994","article-title":"Acute Systemic Inflammation Impairs Endothelium-Dependent Dilatation in HuMans","volume":"102","author":"Hingorani","year":"2000","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.5.414","article-title":"Arterial Stiffness and Central Blood Pressure, as Determined by Pulse Wave Analysis, in Rheumatoid Arthritis","volume":"62","author":"Klocke","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-13-176","article-title":"Risk of Subarachnoid Haemorrhage in People Admitted to Hospital With Selected Immune-Mediated Diseases: Record-Linkage Studies","volume":"13","author":"Ramagopalan","year":"2013","journal-title":"BMC Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-12-41","article-title":"Risk of Subsequent Ischemic and Hemorrhagic Stroke in Patients Hospitalized for Immune-Mediated Diseases: A Nationwide Follow-Up Study From Sweden","volume":"12","author":"Z\u00f6ller","year":"2012","journal-title":"BMC Neurol"},{"key":"B11","article-title":"Association Between Primary Sj\u00f6gren Syndrome, Cardiovascular and Cerebrovascular Disease: A Systematic Review and Meta-Analysis","author":"Yong","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"B12","article-title":"Risk of Cardiovascular Involvement in Patients With Primary Sj\u00f6gren\u2019s Syndrome: A Large-Scale Cross-Sectional Cohort Study","volume":"44","author":"Cai","year":"2019","journal-title":"Acta Reumatol Port"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12346","article-title":"Cardiovascular Disease Risk Burden in Primary Sj\u00f6gren\u2019s Syndrome: Results of a Population-Based Multicentre Cohort Study","volume":"278","author":"Bartoloni","year":"2015","journal-title":"J Intern Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160185","article-title":"The Risk of Deep Venous Thrombosis and Pulmonary Embolism in Primary Sj\u00f6gren Syndrome: A General Population-Based Study","volume":"44","author":"Avina-Zubieta","year":"2017","journal-title":"J Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2573-7","article-title":"Primary Sj\u00f6gren\u2019s Syndrome and Risk of Ischemic Stroke: A Nationwide Study","volume":"33","author":"Chiang","year":"2014","journal-title":"Clin Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23821","article-title":"Cardiovascular Morbidity and Mortality in Primary Sj\u00f6gren\u2019s Syndrome: A Systematic Review and Meta-Analysis","volume":"72","author":"Beltai","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13075-015-0613-6","article-title":"Subclinical Atherosclerosis and Impaired Bone Health in Patients With Primary Sjogren\u2019s Syndrome: Prevalence, Clinical and Laboratory Associations","volume":"17","author":"Gravani","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B18","article-title":"New Parameters for Identifying Subclinical Atherosclerosis in Patients With Primary Sj\u00f6gren\u2019s Syndrome: A Pilot Study","volume":"32","author":"Atzeni","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4330-9","article-title":"Evaluation of Subclinical Atherosclerosis by Ultrasound Radiofrequency Data Technology in Patients With Primary Sj\u00f6gren\u2019s Syndrome","volume":"38","author":"Ozisler","year":"2019","journal-title":"Clin Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.55.3472","article-title":"Is There an Increased Arterial Stiffness in Patients With Primary Sj\u00f6gren\u2019s Syndrome","volume":"55","author":"Demirci","year":"2016","journal-title":"Intern Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22493","article-title":"Prevalence of and Factors Associated With Increased Arterial Stiffness in Patients With Primary Sj\u00f6gren\u2019s Syndrome","volume":"67","author":"Sabio","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000413","article-title":"Asymptomatic Atherosclerosis in Primary Sj\u00f6gren Syndrome: Correlation Between Low Ankle Brachial Index and Autoantibodies Positivity","volume":"22","author":"Garcia","year":"2016","journal-title":"J Clin Rheumatol"},{"key":"B23","article-title":"Is the Heart Affected in Primary Sj\u00f6gren\u2019s Syndrome? An Echocardiographic Study","volume":"26","author":"Vassiliou","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12258","article-title":"Assessment of the Relationship Between Aortic Stiffness and Left Ventricular Functions With Echocardiography in Patients With Sj\u00f6gren\u2019s Syndrome","volume":"17","author":"Ci\u00e7ek","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22227","article-title":"Cardiovascular Risk Factors in Women With Primary Sj\u00f6gren\u2019s Syndrome: United Kingdom Primary Sj\u00f6gren\u2019s Syndrome Registry Results","volume":"66","author":"Juarez","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-3072-1","article-title":"Metabolic Syndrome in Sj\u00f6gren\u2019s Syndrome Patients: A Relevant Concern for Clinical Monitoring","volume":"35","author":"Augusto","year":"2016","journal-title":"Clin Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310367504","article-title":"Cardiovascular Risk Factors in Primary Sj\u00f6gren\u2019s Syndrome: A Case-Control Study in 624 Patients","volume":"19","author":"P\u00e9rez-De-Lis","year":"2010","journal-title":"Lupus"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei190","article-title":"Serum Lipid Levels in Sj\u00f6gren\u2019s Syndrome","volume":"45","author":"Lodde","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1093\/rheumatology\/kel349","article-title":"Traditional Cardiovascular Risk Factors in Primary Sj\u00f6gren\u2019s Syndrome - Role of Dyslipidaemia","volume":"45","author":"Gerli","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/acr.23015","article-title":"Comorbidities in Patients With Primary Sj\u00f6gren\u2019s Syndrome and Systemic Lupus Erythematosus: A Comparative Registries-Based Study","volume":"69","author":"R\u00faa-Figueroa","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/xef8uz","article-title":"Traditional and Disease-Related Non-Computed Variables Affect Algorithms for Cardiovascular Risk Estimation in Sj\u00f6gren\u2019s Syndrome and Rheumatoid Arthritis","author":"Cafaro","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12941","article-title":"Concomitant Ro\/SSA and La\/SSB Antibodies are Biomarkers for the Risk of Venous Thromboembolism and Cerebral Infarction in Primary Sj\u00f6gren\u2019s Syndrome","volume":"286","author":"Mofors","year":"2019","journal-title":"J Intern Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12988","article-title":"Interplay of Anti-SSA\/SSB Status and Hypertension in Determining Cardiovascular Risk in Primary Sj\u00f6gren\u2019s Syndrome","volume":"287","author":"Bartoloni","year":"2020","journal-title":"J Intern Med"},{"key":"B34","article-title":"Application of Artificial Neural Network Analysis in the Evaluation of Cardiovascular Risk in Primary Sj\u00f6gren\u2019s Syndrome: A Novel Pathogenetic Scenario","author":"Bartoloni","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20117","article-title":"Functional Impairment of the Arterial Wall in Primary Sj\u00f6gren\u2019s Syndrome: Combined Action of Immunologic and Inflammatory Factors","volume":"62","author":"Gerli","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B36","first-page":"36","article-title":"Angiogenic T Cells in Primary Sj\u00f6gren\u2019s Syndrome: A Double-Edged Sword","author":"Alunno","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-012-2019-z","article-title":"Lupus Anticoagulant: A Marker for Stroke and Venous Thrombosis in Primary Sj\u00f6gren\u2019s Syndrome","volume":"31","author":"Pasoto","year":"2012","journal-title":"Clin Rheumatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-005-0599-5","article-title":"Endothelial Dysfunction in Patients With Primary Sj\u00f6gren\u2019s Syndrome","volume":"25","author":"Pirildar","year":"2005","journal-title":"Rheumatol Int"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/nu13062072","article-title":"Cardiovascular Risk and Endothelial Dysfunction in Primary Sjogren Syndrome Is Related to the Disease Activity","volume":"13","author":"\u0141uczak","year":"2021","journal-title":"Nutrients"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu320","article-title":"Characterization of Circulating Endothelial Microparticles and Endothelial Progenitor Cells in Primary Sj\u00f6gren\u2019s Syndrome: New Markers of Chronic Endothelial Damage","volume":"54","author":"Bartoloni","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4906(01)01922-6","article-title":"Atherosclerosis as an Infectious, Inflammatory and Autoimmune Disease","volume":"22","author":"Shoenfeld","year":"2001","journal-title":"Trends Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis - an Inflammatory Disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jaut.2007.02.004","article-title":"The Pathogenesis of Atherosclerosis in Autoimmune Rheu- Matic Diseases: Roles of Inflammation and Dyslipidemia","volume":"28","author":"Hahn","year":"2007","journal-title":"J Autoimmun"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/s1568-9972(02)00100-3","article-title":"Accelerated Atherogenesis in Autoimmune Rheu- Matic Diseases","volume":"1","author":"Bacon","year":"2002","journal-title":"Autoimmun Rev"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000021125.83697.21","article-title":"Predisposition to Atherosclerosis by Infections: Role of Endothelial Dysfunction","volume":"106","author":"Prasad","year":"2002","journal-title":"Circulation"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.24.2919","article-title":"Transfer of CD4 + T Cells Aggravates Atherosclerosis in Immun- Odeficient Apolipoprotein E Knockout Mice","volume":"102","author":"Zhou","year":"2000","journal-title":"Circulation"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.99.17.2227","article-title":"Immunolocalization of B 2-Glycoprotein I (Apolipoprotein H) to Human Atherosclerotic Plaques","volume":"99","author":"George","year":"1999","journal-title":"Circulation"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1177\/096120339700600908","article-title":"Atherosclerosis in LDL-Receptor Knockout Mice is Accelerated by Immunization With Anticardiolipin Antibodies","volume":"6","author":"George","year":"1997","journal-title":"Lupus"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1995.tb06652.x","article-title":"Autoantibodies Against Oxidized Low Density Lipoproteins (oxLDL): Characterization of Antibody Isotype, Subclass, Affinity and Effect on the Macrophage Uptake of oxLDL","volume":"102","author":"Wu","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1191\/096120399678847434","article-title":"Antibodies Against Lysophosphatidylcholine and Oxidized LDL in Patients With SLE","volume":"8","author":"Wu","year":"1999","journal-title":"Lupus"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.15.4.441","article-title":"Patients With Early-Onset Peripheral Vascular Disease Have Increased Levels of Autoantibodies Against Oxidized LDL","volume":"15","author":"Bergmark","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/art.21475","article-title":"Precocious Intima-Media Thickening in Patients With Primary Sj\u00f6gren\u2019s Syndrome","volume":"52","author":"Vaudo","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B53","article-title":"Serum Calprotectin is a Biomarker of Carotid Atherosclerosis in Patients With Primary Sj\u00f6gren\u2019s Syndrome","volume":"34","author":"Balarini","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-009-1099-x","article-title":"Prevalence of Abnormal Ankle Brachial Index in Patients With Primary Sj\u00f6gren\u2019s Syndrome","volume":"28","author":"Rachapalli","year":"2009","journal-title":"Clin Rheumatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.55.3472","article-title":"Is There an Increased Arterial Stiffness in Patients With Primary Sj\u00f6gren\u2019s Syndrome","volume":"55","author":"Demici","year":"2016","journal-title":"Intern Med"},{"key":"B56","article-title":"Phagocyte-Specific S100A8\/A9 is Upregulated in Primary Sj\u00f6gren\u2019s Syndrome and Triggers the Secretion of Pro-Inflammatory Cytokines In Vitro","volume":"35","author":"Nicaise","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.109.189761","article-title":"Dickkopf-1 Enhances Inflammatory Interaction Between Platelets and Endothelial Cells and Shows Increased Expression in Atherosclerosis","volume":"29","author":"Ueland","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12115","article-title":"The P2X7 Receptor-Inflammasome Complex has a Role in Modulating the Inflammatory Response in Primary Sj\u00f6gren\u2019s Syndrome","volume":"274","author":"Baldini","year":"2013","journal-title":"J Intern Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.7150\/ntno.19449","article-title":"Nanoliposomes for Safe and Efficient Therapeutic mRNA Delivery: A Step Toward Nanotheranostics in Inflammatory and Cardiovascular Diseases as Well as Cancer","volume":"1","author":"Abraham","year":"2017","journal-title":"Nanotheranostics"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.10.014","article-title":"Efficacy of Aspirin for the Primary Prevention of Thrombosis in Patients With Antiphospholipid Antibodies: An International and Collaborative Meta-Analysis","volume":"13","author":"Arnaud","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2015.06.004","article-title":"Reality of a Vaccine in the Prevention and Treatment of Atherosclerosis","volume":"46","author":"Garc\u00eda-Gonzalez","year":"2015","journal-title":"Arch Med Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-15-0167","article-title":"Modulation of Autoimmunity and Atherosclerosis \u2013 Common Targets and Promising Translational Approaches Against Disease","volume":"79","author":"Ketelhuth","year":"2015","journal-title":"Circ J"},{"key":"B63","doi-asserted-by":"publisher","first-page":"796891","DOI":"10.1155\/2013\/796891","article-title":"Site-Specific Antioxidative Therapy for Prevention of Atherosclerosis and Cardiovascular Disease","volume":"2013","author":"Otani","year":"2013","journal-title":"Oxid Med Cell Longev"},{"key":"B64","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nrcardio.2015.5","article-title":"Anti-Inflammatory Therapies for Atherosclerosis","volume":"12","author":"Back","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrrheum.2012.53","article-title":"Topical and Systemic Medications for the Treatment of Primary Sj\u00f6gren\u2019s Syndrome","volume":"8","author":"Ramos-Casals","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001064","article-title":"Efficacy and Safety of Topical and Systemic Medications: A Systematic Literature Review Informing the EULAR Recommendations for the Management of Sj\u00f6gren\u2019s Syndrome","volume":"5","author":"Brito-Zer\u00f3n","year":"2019","journal-title":"RMD Open"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-014-9901-4","article-title":"The Efficacy of Topical 0.05% Cyclosporine A in Patients With Dry Eye Disease Associated With Sj\u00f6gren\u2019s Syndrome","volume":"34","author":"Deveci","year":"2014","journal-title":"Int Ophthalmol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.08.001","article-title":"Lifitegrast Ophthalmic Solution 5.0% Versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study","volume":"122","author":"Tauber","year":"2015","journal-title":"Ophthalmology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II Pathophysiology Report","volume":"15","author":"Bron","year":"2017","journal-title":"Ocul Surf"},{"key":"B70","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/s1542-0124(12)70081-2","article-title":"The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop","volume":"5","year":"2007","journal-title":"Ocul Surf"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1993.01090010023009","article-title":"Lymphocytic Infiltration of the Conjunctiva and the Salivary Gland in Sjogren\u2019s Syndrome","volume":"111","author":"Hikichi","year":"1993","journal-title":"Arch Ophthalmol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.04.003","article-title":"Analysis of Tear Cytokines and Clinical Correlations in Sjogren Syndrome Dry Eye Patients and Non-Sjogren Syndrome Dry Eye Patients","volume":"156","author":"Lee","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173301","article-title":"Analysis of Th17-Associated Cytokines and Clinical Correlations in Patients With Dry Eye Disease","volume":"12","author":"Liu","year":"2017","journal-title":"PloS One"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(90)32478-8","article-title":"Conjunctival Cytologic Features of Primary Sjogren\u2019s Syndrome","volume":"97","author":"Pflugfelder","year":"1990","journal-title":"Ophthalmology"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1076\/ceyr.19.3.201.5309","article-title":"Altered Cytokine Balance in the Tear Fluid and Conjunctiva of Patients With Sjogren\u2019s Syndrome Keratoconjunctivitis Sicca","volume":"19","author":"Pflugfelder","year":"1999","journal-title":"Curr Eye Res"},{"key":"B76","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1365-2559.1988.tb02024.x","article-title":"Conjunctival Biopsy in Sjogren\u2019s Syndrome: Correlations Between Histological and Immunohistochemical Features","volume":"13","author":"Raphael","year":"1988","journal-title":"Histopathology"},{"key":"B77","article-title":"Pro- and Anti-Inflammatory Forms of Interleukin- 1 in the Tear Fluid and Conjunctiva of Patients With Dry-Eye Disease","volume":"42","author":"Solomon","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e31803dcda2","article-title":"Interleukin- 6 and Tumor Necrosis Factor-Alpha Levels in Tears of Patients With Dry Eye Syndrome","volume":"26","author":"Yoon","year":"2007","journal-title":"Cornea"},{"key":"B79","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ophtha.2014.07.048","article-title":"Matrix Metalloproteinase 9 and Transglutaminase 2 Expression at the Ocular Surface in Patients With Different Forms of Dry Eye Disease","volume":"122","author":"Aragona","year":"2015","journal-title":"Ophthalmology"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-5359-5_91","article-title":"A Unified Theory of the Role of the Ocular Surface in Dry Eye","volume":"438","author":"Stern","year":"1998","journal-title":"Adv Exp Med Biol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(86)33528-0","article-title":"The Autoimmune Nature of Aqueous Tear Deficiency","volume":"93","author":"Pflugfelder","year":"1986","journal-title":"Ophthalmology"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-021-01708-1","article-title":"Topical Cyclosporine a (0,05%) Treatment in Dry Eye Patients: A Comparison Study of Sj\u00f6gren\u2019s Syndrome Versu Non Sj\u00f6gren\u2019s Syndrome","volume":"41","author":"Cubuk","year":"2021","journal-title":"Int Optalmol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2014.12.006","article-title":"Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta-Analysis","volume":"13","author":"Wan","year":"2015","journal-title":"Ocul Surf"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1587470","article-title":"Evaluation of the Efficacy and Safety of a Novel 0.05% Cyclosporin a Topical Nanoemulsion in Primary Sj\u00f6gren\u2019s Syndrome Dry Eye","volume":"28","author":"Kang","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2009.090319","article-title":"Systemic and Local Interleukin-17 and Linked Cytokines Associated With Sjogren\u2019s Syndrome Immunopathogenesis","volume":"175","author":"Katsifis","year":"2009","journal-title":"Am J Pathol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.4.2898","article-title":"Identification of IL-18 and Th17 Cells in Salivary Glands of Patients With Sjogren\u2019s Syndrome, and Amplifi- Cation of IL-17-Mediated Secretion of Inflammatory Cytokines From Salivary Gland Cells by IL-18","volume":"181","author":"Sakai","year":"2008","journal-title":"J Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/art.23214","article-title":"Salivary Gland Tissue Expression of Interleukin-23 and Interleukin-17 in Sjogren\u2019s Syndrome: Findings in Humans and Mice","volume":"58","author":"Nguyen","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1014","article-title":"Treatment of Primary Sj\u00f6gren Syndrome: A Systematic Review","volume":"304","author":"Ramos-Casals","year":"2010","journal-title":"JAMA"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-007-0627-2","article-title":"Efficacy and Safety of Mizoribine for the Treatment of Sj\u00f6gren\u2019s Syndrome: A Multicenter Open-Label Clinical Trial","volume":"17","author":"Nakayamada","year":"2007","journal-title":"Mod Rheumatol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-008-0141-1","article-title":"Efficacy and Safety of Rebamipide for the Treatment of Dry Mouth Symptoms in Patients With Sj\u00f6gren\u2019s Syndrome: A Double-Blind Placebo-Controlled Multicenter Trial","volume":"19","author":"Sugai","year":"2009","journal-title":"Mod Rheumatol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05429-1","article-title":"Biologic Therapy in Sj\u00f6gren\u2019s Syndrome","volume":"40","author":"Shao","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009208","article-title":"Health-Related Quality of Life and Psychological Status of Women With Primary Sj\u00f6gren\u2019s Syndrome: A Cross-Sectional Study of 304 Chinese Patients","volume":"96","author":"Liu","year":"2017","journal-title":"Medicine"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep141","article-title":"Health-Related Quality of Life, Employment and Disability in Patients With Sj\u00f6gren\u2019s Syndrome","volume":"48","author":"Meijer","year":"2009","journal-title":"Rheumatology"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1080\/030097400750001761","article-title":"Health-Related Quality of Life in Primary Sj\u00f6gren\u2019s Syn- Drome, Rheumatoid Arthritis and Fibromyalgia Compared to Normal Population Data Using SF-36","volume":"29","author":"Str\u00f6mbeck","year":"2000","journal-title":"Scand J Rheumatol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-010-0329-z","article-title":"Evaluation of Quality of Life in Relation to Anxiety and Depression in Primary Sj\u00f6gren\u2019s Syndrome","volume":"20","author":"Inal","year":"2010","journal-title":"Mod Rheumatol"},{"key":"B96","article-title":"Sleep Quality in Patients With Primary Sj\u00f6gren\u2019s Syndrome","volume":"34","author":"Priori","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"B97","article-title":"Fatigue in Sj\u00f6gren\u2019s Syndrome: Relationship With Fibromyalgia, Clinical and Biologic Features","author":"Priori","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203249","article-title":"EULAR Evidence-Based and Consensus-Based Recommendations on the Management of Medium to High-Dose Glucocorticoid Therapy in Rheumatic Diseases","volume":"72","author":"Duru","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1276562","article-title":"Glucocorticoid-Targeted Therapies for the Treatment of Rheumatoid Arthritis","volume":"26","author":"Strehl","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01545","article-title":"A General Introduction to Glucocorticoid Biology","volume":"10","author":"Timmermans","year":"2919","journal-title":"Front Immunol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0083-6729(08)60646-9","article-title":"11 Beta-Hydroxysteroid Dehydrogenase","volume":"57","author":"Stewart","year":"1999","journal-title":"Vitam Horm"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0898","article-title":"Genomic and Non-Genomic Effects of Glucocorticoids","volume":"4","author":"Stahn","year":"2008","journal-title":"Nat Rev Rheumatol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.1","article-title":"Immune Regulation by Glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker017","article-title":"Prevalence of Long-Term Oral Glucocorticoid Prescriptions in the UK Over the Past 20 Years","volume":"50","author":"Fardet","year":"2011","journal-title":"Rheumatology"},{"key":"B105","article-title":"Prednisone and Piroxicam for Treatment of Primary Sj\u00f6gren\u2019s Syndrome","volume":"11","author":"Fox","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2015.03.027","article-title":"How are We Treating Our Systemic Patients With Primary Sj\u00f6gren Syndrome? Analysis of 1120 Patients","volume":"27","author":"Gheitasi","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"B107","article-title":"Severe, Life-Threatening Phenotype of Primary Sj\u00f6gren\u2019s Syndrome: Clinical Charac- Terisation and Outcomes in 1580 Patients (the GEAS-SS Registry)","author":"Flores-Ch\u00e0vez","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07950.x","article-title":"Corticosteroid-Induced Clinical Adverse Events: Frequency, Risk Factors and Patient\u2019s Opinion","volume":"157","author":"Fardet","year":"2007","journal-title":"Br J Dermatol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199101173240303","article-title":"A Randomized Study of the Effect of Withdrawing Hydroxychloroquine Sulfate in Systemic Lupus Erythematosus","volume":"324","year":"1991","journal-title":"N Engl J Med"},{"key":"B110","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-0348-0706-7_7","article-title":"B-Cell Targeted Therapies in Primary Sj\u00f6gren Syndrome","volume-title":"Drugs Targeting B-Cells in Autoimmune Diseases","author":"Brito-Zer\u00f3n","year":"2014"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7682","article-title":"Effects of Hydroxychloroquine on Symptomatic Improvement in Pri- Mary Sj\u00f6gren Syndrome: The JOQUER Randomized Clinical Trial","volume":"312","author":"Gottenberg","year":"2014","journal-title":"JAMA"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key167","article-title":"Adherence to Hydroxychloroquine Improves Long-Term Suvival of Patients With Systemic Lupus Erythematosus","volume":"57","author":"Hsu","year":"2018","journal-title":"Rheumatology"},{"key":"B113","unstructured":"KimAHJ\n          FDA NewsFDA Approves Hydroxychloroquine New Drug Application to Adress COVID-19 Related Shortage"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31180-6","article-title":"Hydroxychloroquine or Chloroquine With or Without a Marolide for Treatment of COVID-19: A Multinational Registry Analysis","author":"Mehra","year":"2020","journal-title":"Lancet"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1080\/15563650500514558","article-title":"Chronic Hydroxychloroquine Use Associated With QT Prolongation and Refractory Ventricular Arrhythmia","volume":"44","author":"Chen","year":"2006","journal-title":"Clin Toxicol (Phila)"},{"key":"B116","article-title":"Methotrexate in Primary Sj\u00f6gren\u2019s Syndrome","volume":"14","author":"Skopouli","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"B117","article-title":"A Double Blind Placebo Controlled Trial of Azathioprine in the Treatment of Primary Sj\u00f6gren\u2019s Syndrome","volume":"25","author":"Price","year":"1998","journal-title":"J Rheumatol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.767333","article-title":"Primary Sj\u00f6gren Syndrome: An Update on Current Pharmacotherapy Options and Future Directions","volume":"14","author":"Brito-Zer\u00f2n","year":"2013","journal-title":"Exp Opin Pharmacother"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.060905","article-title":"Safety and Efficacy of Leflunomide in Primary Sj\u00f6gren\u2019s Syndrome: A Phase II Pilot Study","volume":"66","author":"Van Woerkom","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2007.06.002","article-title":"Primary Sj\u00f6gren\u2019s Syndrome: Current and Prospective Therapies","volume":"37","author":"Thanou-Stavraki","year":"2008","journal-title":"Semin Arthritis Rheumatol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1186\/ar2322","article-title":"Mycophenolate Sodium Treatment in Patients With Primary Sj\u00f6gren Syn- Drome: A Pilot Trial","volume":"9","author":"Willeke","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"B122","article-title":"Cyclosporin A Therapy in Patients With Primary Sj\u00f6gren\u2019s Syndrome: Results at One Year","author":"Drosos","year":"1986","journal-title":"Scand J Rheumatol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3360-4","article-title":"A Phase II Investigator-Initiated Pilot Study With Low-Dose Cyclosporine A for the Treatment of Articular Involvement in Primary Sj\u00f6gren\u2019s Syndrome","volume":"35","author":"Kedor","year":"2016","journal-title":"Clin Rheumatol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sj\u00f6gren\u2019s Syndrome: A Twelve-Week Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheumatol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1002\/art.20146","article-title":"Inefficacy of Infliximab in Primary Sj\u00f6gren\u2019s Syndrome: Results of the Randomized, Controlled Trial of Remicade in Primary Sj\u00f6gren\u2019s Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheumatol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030123","article-title":"Interleukin-1 Inhibition and Fatigue in Primary Sj\u00f6gren\u2019s Syndrome - a Double Blind, Randomised Clinical Trial","volume":"7","author":"Norheim","year":"2012","journal-title":"PloS One"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-219882","article-title":"Interleukin 6 Receptor Inhibition in Primary Sj\u00f6gren Syndrome: A Multicenter Double-Blind Randomised Placebo-Controlled Trial","author":"Felten","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 Costimulation: From Mechanism to Therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.2090","article-title":"Efficacy and Safety of Abatacept in Active Primary Sj\u00f6gren\u2019s Syndrome: Results of a Phase III, Randomised, Placebo-Controlled Trial","volume":"80","author":"Baer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.33","article-title":"The BAFF\/APRIL System in SLE Pathogenesis","volume":"10","author":"Vincent","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02698","article-title":"Inhibition of Membrane-Bound BAFF by the Anti BAFF Antibody Belimumab","volume":"9","author":"Kowalczyk-Quintas","year":"2018","journal-title":"Front Immunol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and Safety of Belimumab in Primary Sjogren\u2019s Syndrome: Results of the BELISS Open-Label Phase II Study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev257","article-title":"Efficacy and Safety of Belimumab Given for 12 Months in Primary Sjogren\u2019s Syndrome: The BELISS Open-Label Phase II Study","volume":"54","author":"De Vita","year":"2015","journal-title":"Rheumatology"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.001","article-title":"CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies","volume":"47","author":"Beers","year":"2010","journal-title":"Semin Hematol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.05.007","article-title":"Action and Resistance of Monoclonal CD20 Antibodies Therapy in B-Cell Non-Hodgkin Lymphomas","volume":"41","author":"P\u00e9rez-Callejo","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"B136","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1053\/sonc.2002.30156","article-title":"Rituximab: Mechanism of Action and Resistance","volume":"29","author":"Maloney","year":"2002","journal-title":"Semin Oncol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.7326\/m13-1085","article-title":"Treatment of Primary Sj\u00f6gren Syndrome With Rituximab: A Randomized Trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1002\/art.22536","article-title":"Improvement of Sj\u00f6gren\u2019s Syndrome After Two Infusions of Rituximab (Anti-Cd20)","volume":"57","author":"Devauchelle-Pensec","year":"2007","journal-title":"Arthritis Rheumatol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of Fatigue in Sj\u00f6gren Syndrome With Rituximab: Results of a Randomised, Double-Blind, Placebo-Controlled Pilot Study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann Rheumatol Dis"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1002\/art.37850","article-title":"Rituximab Therapy for Primary Sj\u00f6gren\u2019s Syndrome: An Open-Label Clinical Trial and Mechanistic Analysis","volume":"65","author":"St Clair","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1002\/art.27314","article-title":"Effectiveness of Rituximab Treatment in Primary Sj\u00f6gren\u2019s Syndrome: A Randomized, Double-Blind, Placebo- Controlled Trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheumatol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1002\/art.24903","article-title":"Clinical and Histologic Evidence of Salivary Gland Restoration Supports the Efficacy of Rituximab Treatment in Sj\u00f6gren\u2019s Syndrome","volume":"60","author":"Pijpe","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208304","article-title":"Towards Personalised Treatment in Primary Sj\u00f6gren\u2019s Syndrome: Baseline Parotid Histopathology Predicts Responsiveness to Rituximab Treatment","volume":"75","author":"Delli","year":"2016","journal-title":"Ann Rheumatol Dis"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212268","article-title":"Effect of Rituximab on a Salivary Gland Ultrasound Score in Primary Sj\u00f6gren\u2019s Syndrome: Results of the TRACTISS Randomised Double-Blind Multicentre Substudy","volume":"77","author":"Fisher","year":"2018","journal-title":"Ann Rheumatol Dis"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1002\/art.40093","article-title":"Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sj\u00f6gren\u2019s Syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200460","article-title":"Responsiveness of Disease Activity Indices ESSPRI and ESSDAI in Patients With Primary Sj\u00f6gren\u2019s Syndrome Treated With Rituximab","volume":"71","author":"Meiners","year":"2012","journal-title":"Ann Rheumatol Dis"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1002\/art.21260","article-title":"Rituximab Treatment in Patients With Primary Sj\u00f6gren\u2019s Syndrome: An Open-Label Phase II Study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheumatol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11095-019-2624-5","article-title":"Concentration and Glycoform of Rituximab in Plasma of Patients With B Cell Non-Hodgkin\u2019s Lymphoma","volume":"36","author":"Yonezawa","year":"2019","journal-title":"Pharm Res"},{"key":"B149","article-title":"Sequential Therapy With Belimumab Followed by Rituximab in Sj\u00f6gren\u2019s Syndrome Associated With B-Cell Lymphoproliferation and Overexpression of BAFF: Evidence for Long-Term Efficacy","volume":"32","author":"De Vita","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109704","article-title":"Molecular Mechanisms and Clinical Application of Iguratimod: A Review","volume":"122","author":"Jiang","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/356040","article-title":"Regulatory Effect of Iguratimod on the Balance of Th Subsets and Inhibition of Inflammatory Cytokines in Patients With Rheumatoid Arthritis","volume":"2015","author":"Xu","year":"2015","journal-title":"Mediators Inflamm"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.7648","article-title":"Iguratimod Prevents Ovariectomy-Induced Bone Loss and Suppresses Osteoclastogenesis via Inhibition of Peroxisome Proliferator-Activated Receptor-\u03b3","volume":"16","author":"Wu","year":"2017","journal-title":"Mol Med Rep"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.621208","article-title":"Effectiveness and Safety of Iguratimod in Treating Primary Sj\u00f6gren\u2019s Syndrome: A Systematic Review and Meta-Analysis","volume":"2021","author":"Pu","year":"2021","journal-title":"Front Pharmacol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1002\/art.39204","article-title":"Molecular Subsetting of Interferon Pathways in Sj\u00f6gren\u2019s Syndrome","volume":"67","author":"Hall","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.5743","article-title":"BIIB059, a Humanized Monoclonal Antibody Targeting BDCA2 on Plasmacytoid Dendritic Cells (pDC), Shows Dose-Related Efficacy in the Phase 2 LILAC Study in Patients (Pts) With Active Cutaneous Lupus Erythematosus (CLE) [Abstract Op0193]","author":"Werth","year":"2020","journal-title":"Ann Rheumatol Dis"},{"key":"B156","unstructured":"ClinicalTrials.gov"},{"key":"B157","unstructured":"ClinicalTrials.gov2021"},{"key":"B158","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): Discovery and Development of an Oral Drug to Treat Multiple Sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00018-1","article-title":"Safety and Efficacy of the Selective Sphingosine 1-Phosphate Receptor Modula- Tor Ozanimod in Relapsing Multiple Sclerosis (RADIANCE): A Randomised, Placebo-Controlled, Phase 2 Trial","volume":"15","author":"Cohen","year":"2016","journal-title":"Lancet Neurol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.drudis.2015.07.008","article-title":"Small-Molecule Kinase Inhibitors: An Analysis of FDA-Approved Drugs","volume":"21","author":"Wu","year":"2016","journal-title":"Drug Discov Today"},{"key":"B161","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1136\/annrheumdis-2018-eular.4373","article-title":"AB0536 Rapamycin Attenuates Symptom and Restores the Balance of Th17\/Treg in Refractory Primary Sj\u00f6gren\u2019s Syndrome","volume":"77","author":"Hao","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-eular.5191","article-title":"THU0245 Mammalian Target of Rapamycin Pathway Might Contribute the Minor Salivary Gland Changes in Both Sj\u00f6gren\u2019s Syn- Drome and Systemic Sclerosis Patients","volume":"76","author":"Gumus","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-19159","article-title":"Rapamycin Eye Drops Suppress Lacrimal Gland Inflammation in a Murine Model of Sj\u00f6gren\u2019s Syndrome","volume":"58","author":"Shah","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B164","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1136\/annrheumdis-2017-eular.4014","article-title":"THU0243 Can the Increase of Lobules\/Foci Ratio be Histopathological Evidence of Primary Sj\u00f6gren\u2019s Syndrome","volume":"76","author":"Unal","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1186\/s13167-016-0052-8","article-title":"The Status of Glucocorticoid-Induced Leucine Zipper Protein in the Salivary Glands in Sj\u00f6grens Syndrome: Predictive and Prognostic Potentials","volume":"7","author":"Qin","year":"2016","journal-title":"EPMA J"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez142","article-title":"Treatment of Sj\u00f6gren\u2019s Syndrome: Current Therapy and Future Directions","volume":"60","author":"Fox","year":"2021","journal-title":"Rheumatology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.879516\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T09:59:59Z","timestamp":1652349599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.879516\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":166,"alternative-id":["10.3389\/fimmu.2022.879516"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.879516","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,6]]},"article-number":"879516"}}